Bone Therapeutics has developed an allogeneic, off-the-shelf bone cell therapy product, ALLOB , and an enhanced viscosupplement, JTA-004, which target 3 bone indications in clinical trials and offer the potential for additional product extensions.
In addition, Bone Therapeutics is conducting preclinical research on next generation product candidates such as BT-20 and personalized, tissue engineered bone implants for large bone defects and maxillofacial applications.